undamentalytics Newsletter
Sign in

Kazia Therapeutics LTD revenue

Kazia Therapeutics LTD's revenue was $27,211 in fiscal 2025, down 98.2% on the year before. Since fiscal 2016 ($295,921) it has grown at a compound -28.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Jun 20162017Jun 20172018Jun 20182021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 2025
Revenue000110020
Growth on the year before—−36.5%−50.9%+>999%−100.0%——−98.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Kazia Therapeutics LTD $27,211 -98.2% —
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%

Compare with peers

Head to head: KZIA vs LYELAIM vs KZIAIBIO vs KZIA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kazia Therapeutics LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kazia Therapeutics LTD.